Gerritsen, Winald

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 3,395

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 2,796

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,511

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 765

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

Fizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 185

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

Melief, C. J. M., Welters, M. J. P., Vergote, I., Kroep, J. R., Kenter, G. G., Ottevanger, P. B., Tjalma, W. A. A., Denys, H., van Poelgeest, M. I. E., Nijman, H. W., et al. (2020) · Science Translational Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 134

Tissue Inhibitor of Metalloproteinase-3 Expression from an Oncolytic Adenovirus Inhibits Matrix Metalloproteinase Activity In vivo without Affecting Antitumor Efficacy in Malignant Glioma

Lamfers, M. L. M., Gianni, D., Tung, C.-H., Idema, S., Schagen, F. H. E., Carette, J. E., Quax, P. H. A., Van Beusechem, V. W., Vandertop, W. P., Dirven, C. M. F., et al. (2005) · Cancer Research

Virus-based gene therapy researchProtease and Inhibitor Mechanisms

Cited by 52

Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11

Oosterhoff, D., Overmeer, R. M., de Graaf, M., van der Meulen, I. H., Giaccone, G., van Beusechem, V. W., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2005) · British Journal of Cancer

Virus-based gene therapy researchCancer therapeutics and mechanisms

Cited by 26